COVID-19 Farmakoterapi Effektivitet i VA Healthcare System (COPE-VA)
CSP #2038 – COVID-19 Farmakoterapi Effektivitet i VA Healthcare System (COPE-VA)
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.
Studieoversikt
Status
Detaljert beskrivelse
Objectives:
This study will be completed in two phases. In the first phase, the investigators will establish a source population and comprehensively describe the temporal and geographic utilization of COVID-19 pharmacotherapies beginning July 2021. These therapies include casirivimab and imdevimab, bamlanivimab and etesevimab, sotrovimab, nirmatrelvir, molnupiravir, and remdesivir. The investigators will also compare demographic and clinical characteristics of Veterans who are treated or do not receive these therapies. Phase 1 will inform the study design and analytic protocol of Phase 2. Phase 1 will also inform critical policy questions and national guidance regarding COVID-19 pharmacotherapies in the VA healthcare system with the potential to inform policy across other healthcare systems.
In the second phase, the investigators will conduct target trial emulation studies to determine the effectiveness and comparative effectiveness of current pharmacotherapies for COVID-19 in preventing short- and long-term adverse outcomes related to SARS-CoV-2 infection. The investigators will use a sequence of comparative effectiveness studies through emulation to help establish a common framework sharing a similar population, design, and outcomes for a rapid-response, adaptive observational study design to characterize utilization and determine the effectiveness and comparative effectiveness of novel therapeutic agents authorized for the treatment of mild to moderate COVID-19 in Veterans. Phase 2 will provide an infrastructure upon which subsequent observational studies can be performed, which will include other infectious diseases of interest, ultimately ensuring the timeliness and pertinence of VA research.
Research Design and Methodology:
In the first phase, the investigators will conduct a descriptive, retrospective, electronic health record-based study among Veterans aged 18 years with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present. The investigators will describe the geographic distribution (by VISN, state, and distance from place of residence to the closest VAMC and/ COVID-19 infusion facilities) of Veterans receiving each of the COVID-19 antiviral and monoclonal antibody therapies during different periods of SARS-CoV-2 variant circulation (i.e., January 1, 2022, to present for Omicron). The investigators will also compare baseline demographic characteristics, clinical characteristics including underlying medical conditions and prior SARS-CoV-2 infections, SARS-CoV-2 vaccination status, National Institutes of Health (NIH) risk group tiers for prioritization of treatments, concurrent outpatient medications, and time from positive test to treatment among Veterans receiving different antiviral and monoclonal antibody therapies as well as eligible Veterans who are not treated during different periods of SARS-CoV-2 variant circulation. This established framework will also be used to identify Veterans who tested positive for other respiratory viruses, including influenza virus or respiratory syncytial virus (RSV), and other infectious diseases in the same time period and describe their characteristics, risk factors and treatments.
In the second phase, the investigators will conduct retrospective and prospective target trial emulation studies to evaluate the effectiveness and comparative effectiveness of different pharmacotherapies for mild-to-moderate COVID-19 in patients with documented SARS-CoV-2 infection by period of predominant SARS-CoV-2 variant circulation. The established framework will be used to investigate vaccine and pharmacotherapy effectiveness for SARS-CoV-2 and other respiratory viruses, including influenza and respiratory syncytial virus (RSV) and other infectious diseases using observational data from the VHA electronic health records.
Impact Significance:
Data on real-world utilization and clinical outcomes in the Veteran population are needed to inform clinical, operational and research partners in the VA and other healthcare systems on strategies for optimizing the utilization of pharmacotherapies and vaccines against COVID-19 and other infectious diseases. Ongoing evaluations will be essential as new variants emerge, vaccination practices evolve, and new pharmacotherapies are introduced. This study will establish a common framework sharing a similar population, design, and outcomes for a rapid-response, adaptive platform observational study design to characterize utilization and determine the effectiveness and comparative effectiveness of novel therapeutic agents authorized for the treatment of mild to moderate COVID-19, respiratory viruses, including RSV and influenza, and other infectious diseases in Veterans.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: George N Ioannou, MD MS
- Telefonnummer: (206) 277-3136
- E-post: George.Ioannou@va.gov
Studer Kontakt Backup
- Navn: Kristina L Bajema, MD
- Telefonnummer: (503) 220-8262
- E-post: Kristina.Bajema@va.gov
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forente stater, 97207-2964
- Rekruttering
- VA Portland Health Care System, Portland, OR
-
Ta kontakt med:
- George N Ioannou, MD MS
- Telefonnummer: (206) 277-3136
- E-post: George.Ioannou@va.gov
-
Ta kontakt med:
- Kristina L Bajema, MD
- Telefonnummer: (503) 220-8262
- E-post: Kristina.Bajema@va.gov
-
Studiestol:
- Kristina L Bajema, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
VA enrollees infected from January 1, 2022 through February 28, 2022 as an example. Subsequent trials will be executed as the pandemic evolves
Beskrivelse
Inclusion Criteria:
Phase 1:
- Veterans with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present
Phase 2:
- All Veterans alive and in Veterans Health Administration (VHA) care as of January 2018
- Specific exclusion/inclusion criteria and observation periods will be further defined for each sub-study (See outcomes/publications)
Exclusion Criteria:
- VA employees who are not enrollees
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: OTHER
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Feb 2022
This cohort study assessed outpatient Veterans with risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022. The purpose is to describe factors associated with receipt of outpatient COVID-19 pharmacotherapies in the Veterans Affairs (VA) health care system. |
|
Nonhospitalized Veterans in VHA at risk for SARS-CoV-2 Jan-Jul 2022
Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir. The purpose is to measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19. |
|
Outpatient Veterans who tested positive for SARS-CoV-2 from Jan 2022 through Jan 2023
This cohort study evaluated nonhospitalized Veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases. The purpose is to analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA). |
|
Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Jul 2022
Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment. The purpose is to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing Post COVID conditions. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Receipt of any COVID-19 pharmacotherapy, including sotrovimab, nirmatrelvir boosted with ritonavir, molnupiravir, or remdesivir
Tidsramme: January and February 2022
|
The odds of receipt of any COVID-19 pharmacotherapy, including sotrovimab, nirmatrelvir boosted with ritonavir, molnupiravir, or remdesivir were estimated using multivariable logistic regression |
January and February 2022
|
|
Incidence of any hospitalization or all-cause mortality at 30 days and from 31 to 180 days
Tidsramme: January through July 2022
|
Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir. |
January through July 2022
|
|
Monthly receipt of any COVID-19 pharmacotherapy (nirmatrelvir-ritonavir, molnupiravir, sotrovimab, or bebtelovimab)
Tidsramme: January 2022 through January 2023
|
To analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA). |
January 2022 through January 2023
|
|
Cumulative incidence of 31 potential PCCs at 31 -180 days after treatment or a matched index date, including cardiac, pulmonary, renal, thromboembolic, gastrointestinal, neurologic, mental health, musculoskeletal, endocrine, and general conditions
Tidsramme: January through July 2022
|
Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment. |
January through July 2022
|
|
Incidence of any hospitalization or all-cause mortality at 30 days
Tidsramme: April 2022 through March 2023
|
Target trial emulation study in the Veterans Health Administration comparing nirmatrelvir-ritonavir treated versus matched untreated Veterans at risk for severe COVID-19 who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
April 2022 through March 2023
|
|
Prediction of 30-day COVID-19 hospitalization and death in the Omicron era for contemporary clinical and research applications
Tidsramme: March 1, 2022, and March 31, 2023
|
Full models incorporated 84 predictors, including demographics, comorbidities, and receipt of COVID-19 vaccinations and anti-SARS-CoV-2 treatments. Parsimonious models included 19 predictors. The investigators created models for 30-day hospitalization or death, 30-day hospitalization, and 30-day all-cause mortality. The investigators used the Super Learner ensemble machine learning algorithm to fit prediction models. Model performance was assessed with the area under the receiver operating characteristic curve (AUC), Brier scores, and calibration intercepts and slopes in a 20% holdout dataset. |
March 1, 2022, and March 31, 2023
|
|
RSVPreF3 or RSVpreF vaccination compared with no respiratory syncytial virus (RSV) vaccination for the prevention of documented RSV infection and associated health-care use among Veterans
Tidsramme: March 1, 2022, and March 31, 2023
|
The primary outcome was any positive respiratory syncytial virus (RSV) test result occurring from day 14 following the index date until the end of the study period. Secondary outcomes included RSV-associated emergency department or urgent care encounters, RSV-associated acute hospitalizations, RSV associated intensive care unit (ICU) admissions, and death. RSV-associated health-care encounters were defined as any corresponding encounter occurring the day before until 1 day after the eligible positive RSV test result. Death was defined as any death occurring on the day of until 30 days after the eligible positive RSV test result. |
March 1, 2022, and March 31, 2023
|
|
compare disease severity of COVID-19, influenza, and RSV among US Veterans
Tidsramme: August 1, 2022, and March 31, 2023, or between August 1, 2023, and March 31, 2024.
|
This retrospective cohort study analyzed national US Veterans Health Administration electronic health record data of non-hospitalized Veterans who underwent same-day testing for SARS-CoV-2, influenza, and RSV, and were diagnosed with a single infection between August 1, 2022, and March 31, 2023, or between August 1, 2023, and March 31, 2024. Following inverse probability weighting, the cumulative incidence and risk differences (RDs) were calculated for the primary outcomes of 30-day hospitalization, intensive care unit admission, and death, as well as the secondary outcome of long-term death extending through 180 days. |
August 1, 2022, and March 31, 2023, or between August 1, 2023, and March 31, 2024.
|
|
Determine XBB.1.5 COVID-19 vaccine effectiveness (VE) and the extent to which it declines over time
Tidsramme: October 2,2023- January 3, 2024
|
Outcomes were ascertained through 10 May 2024 and included any positive result on a SARS-CoV-2 test from day 10 after the matched index date, subsequent hospitalization within 1 day before or 10 days after the positive result, or death within 30 days after the positive result. Vaccine effectiveness was estimated as 100x (1-risk ratio). |
October 2,2023- January 3, 2024
|
|
Determine if severe SARS-CoV-2 infection increases risk of selected PCCs or death up to 1 year after infection in wild-type (WT), Alpha-transition, Delta, and Omicron eras
Tidsramme: March 2020 and April 2022
|
Investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increases the risk of selected PCCs or death up to 1 year after infection, separately in the wild-type (WT), Alpha-transition, Delta, and Omicron eras and by vaccination status. |
March 2020 and April 2022
|
|
Determined budget cost of providing nirmatrelvir-ritonavir to Veterans with COVID-19 on 30-day healthcare costs to inform procurement strategies in large healthcare systems
Tidsramme: April 2022 through March 2023
|
The decision tree analysis included transition states from cohort entry (i.e., infection and treatment) to emergency department (ED) visit, hospitalization without intensive care unit (ICU) admission, hospitalization with ICU admission, recovery, and death. Decision trees were created for each subgroup and treatment allocation and parameterized with subgroup and treatment specific transition probabilities. In total, 26 trees (13 subgroups and 2 treatment scenarios) were created and parameterized with over 150 transition probabilities. |
April 2022 through March 2023
|
|
Evaluate the impact of different time zero designations on results and inferences from a cohort study comparing the effectiveness of nirmatrelvir ritonavir treatment versus no COVID-19 antiviral treatment in preventing 30-day hospitalization and death
Tidsramme: April 2022-March 2023
|
Identified US Veterans who tested positive for SARS-CoV-2 from April 2022-March 2023 and compared nirmatrelvir-ritonavir versus no treatment using 5 time zero approaches: test-date (treated) versus test-date (untreated) with matching allowing treatment on days 0-5 (approach 1a) or day 0 only (1b), test-date versus test-date with a clone-censor-weight method (1c), treatment date versus test-date (2) with matching, or treatment date versus matched index date (3). |
April 2022-March 2023
|
|
Asses the long-term effectiveness of a single respiratory syncytial virus (RSV) vaccine dose against RSV illness and associated health care use
Tidsramme: September 2023 to March 2024.
|
The primary outcome was any positive RSV test result from day 14 following the matched index date. Secondary outcomes included RSV-associated emergency department or urgent care visits, hospitalizations, or intensive care unit admissions. Vaccine effectiveness was estimated as 100 × (1 - risk ratio). |
September 2023 to March 2024.
|
|
Estimate the long-term vaccine effectiveness (VE) of the 2024-2025 COVID-19 vaccines targeting the KP.2 Omicron variant within the Veterans Health Administration
Tidsramme: August 1, 2024- April 12, 2025
|
Vaccine effectiveness against documented SARS CoV-2 infection, SARS-CoV-2 associated ED/UC visit, SARS-CoV-2 associated hospitalization or SARS-CoV-2 associated death |
August 1, 2024- April 12, 2025
|
|
Compared treatment with oseltamivir versus no antiviral treatment within 6 hours of a positive influenza test
Tidsramme: 1 October 2022-31 January 2023; 1 December 2023-31 March 2024
|
Assessed Veterans who presented to emergency departments in the Veterans Health Administration (VHA) and tested positive for influenza |
1 October 2022-31 January 2023; 1 December 2023-31 March 2024
|
|
Calculated cumulative incidence, risk differences (RDs), and risk ratios (RR) for hospitalization and intensive care unit (ICU) admission at 10 days
Tidsramme: 1 October 2022-31 January 2023; 1 December 2023-31 March 2024
|
Assessed Veterans who presented to emergency departments in the Veterans Health Administration (VHA) and tested positive for influenza |
1 October 2022-31 January 2023; 1 December 2023-31 March 2024
|
|
Calculated cumulative incidence, risk differences (RDs), and risk ratios (RR) for hospitalization and intensive care unit (ICU) admission at death at 30 days
Tidsramme: 1 October 2022-31 January 2023; 1 December 2023-31 March 2024
|
Assessed Veterans who presented to emergency departments in the Veterans Health Administration (VHA) and tested positive for influenza |
1 October 2022-31 January 2023; 1 December 2023-31 March 2024
|
|
Any positive RSV test result from day 14 after the matched index date.
Tidsramme: October 1, 2025, to January 31, 2026; ascertained through May 31, 2026 or 24 weeks
|
The primary outcome was any positive RSV test result from day 14 after the matched index date. |
October 1, 2025, to January 31, 2026; ascertained through May 31, 2026 or 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
RSV-associated emergency department (ED) or urgent care (UC) encounters and RSV-associated hospitalizations
Tidsramme: October 1, 2025, to January 31, 2026; ascertained through May 31, 2026 or 24 weeks
|
Secondary outcomes included RSV-associated emergency department (ED) or urgent care (UC) encounters and RSV-associated hospitalizations |
October 1, 2025, to January 31, 2026; ascertained through May 31, 2026 or 24 weeks
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: George N. Ioannou, MD MS, VA Puget Sound Health Care System Seattle Division, Seattle, WA
- Studiestol: Kristina L Bajema, MD, VA Portland Health Care System, Portland, OR
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2038 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
There is not a plan to make IPD available
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .